Zymeworks (ZYME)
Develops antibody medicines and earns royalties from partner-run therapies.
$27.68
vs last close+0.11 (+0.41%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 96.56% | 68.52M shares | |
|---|---|---|---|
| 208 holders · as of Jun 30, 2026 | |||
| Insiders | 23.46% | 16.65M shares | |
| 7 holders · as of Jul 6, 2026 | |||
| Adds to | 120.02% | ||
70.96M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 120.02%; nothing is left for Other.
13F, as of Jun 30, 2026
208 holders · 68.52M shares · 27 new positions · 88 increased · 74 reduced · 36 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ecor1 Capital, LLC | 22.97M | 32.37% | 0 | Aug 14, 2026 |
| Rubric Capital Management LP | 7.00M | 9.86% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 4.25M | 5.99% | −302.9K | Aug 7, 2026 |
| Perceptive Advisors LLC | 4.18M | 5.89% | +672.9K | Aug 14, 2026 |
| BVF Inc/IL | 3.65M | 5.14% | −85.0K | Aug 14, 2026 |
| Morgan Stanley | 2.23M | 3.14% | −249.3K | Aug 13, 2026 |
| BNP Paribas Asset Management Holding S.A. | 1.78M | 2.51% | −126.9K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.56M | 2.20% | −146.6K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| EcoR1 Capital, LLCincl. EcoR1 Capital Fund Qualified, L.P., Oleg Nodelman | 30.70% | 22.97M | 13D | Nov 19, 2025 |
| Rubric Capital Management LP | 9.49% | 7.00M | 13G | May 15, 2026 |
| Perceptive Advisors LLC | 5.40% | 3.97M | 13G | Apr 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jan 12, 2026 | Mark Hollywoodofficer: EVP & Chief Operating Officer | Sale | 6,120 | $22.67 | 132,913 |
| Jan 12, 2026 | Kenneth Galbraithdirector, officer: Chair & CEO | Sale | 30,424 | $22.67 | 226,842 |
| Jan 12, 2026 | Paul Andrew Mooreofficer: Chief Scientific Officer | Sale | 9,560 | $22.67 | 48,497 |
| Jan 12, 2026 | Jeffrey T. L. Smithofficer: EVP & Chief Medical Officer | Sale | 9,310 | $22.67 | 26,708 |
| Jan 5, 2026 | Paul Andrew Mooreofficer: Chief Scientific Officer | Sale · 2 lots | 20,110 | $25.10 | 31,212 |
| Jan 5, 2026 | Kenneth Galbraithdirector, officer: Chair & CEO | Sale · 2 lots | 54,343 | $25.10 | 158,286 |
| Jan 5, 2026 | Jeffrey T. L. Smithofficer: EVP & Chief Medical Officer | Sale | 10,538 | $25.10 | 18,352 |
| Dec 22, 2025 | Kenneth Galbraithdirector, officer: Chair & CEO | Sale | 47,528 | $27.02 | 133,275 |
House and Senate disclosures
Not reported.